» Articles » PMID: 37760840

Multi-Faceted Role of Cancer-Associated Adipocytes in Colorectal Cancer

Overview
Journal Biomedicines
Date 2023 Sep 28
PMID 37760840
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is one of the most commonly diagnosed types of cancer, especially in obese patients, and the second cause of cancer-related death worldwide. Based on these data, extensive research has been performed over the last decades to decipher the pivotal role of the tumor microenvironment (TME) and its cellular and molecular components in CRC development and progression. In this regard, substantial progress has been made in the identification of cancer-associated adipocytes' (CAAs) characteristics, considering their active role in the CCR tumor niche, by releasing a panel of metabolites, growth factors, and inflammatory adipokines, which assist the cancer cells' development. Disposed in the tumor invasion front, CAAs exhibit a fibroblastic-like phenotype and establish a bidirectional molecular dialogue with colorectal tumor cells, which leads to functional changes in both cell types and contributes to tumor progression. CAAs also modulate the antitumor immune cells' response and promote metabolic reprogramming and chemotherapeutic resistance in colon cancer cells. This review aims to report recent cumulative data regarding the molecular mechanisms of CAAs' differentiation and their activity spectrum in the TME of CRC. A better understanding of CAAs and the molecular interplay between CAAs and tumor cells will provide insights into tumor biology and may open the perspective of new therapeutic opportunities in CRC patients.

Citing Articles

The evolving tumor-associated adipose tissue microenvironment in breast cancer: from cancer initiation to metastatic outgrowth.

Yang Y, Ma X, Li Y, Jin L, Zhou X Clin Transl Oncol. 2024; .

PMID: 39720985 DOI: 10.1007/s12094-024-03831-8.


The Role of Adipocytes Recruited as Part of Tumor Microenvironment in Promoting Colorectal Cancer Metastases.

Ma Y, Nenkov M, Chen Y, Gassler N Int J Mol Sci. 2024; 25(15).

PMID: 39125923 PMC: 11313311. DOI: 10.3390/ijms25158352.


Ginsenosides: an immunomodulator for the treatment of colorectal cancer.

Qian J, Jiang Y, Hu H Front Pharmacol. 2024; 15:1408993.

PMID: 38939839 PMC: 11208871. DOI: 10.3389/fphar.2024.1408993.


Prognostic Impact of Visceral Adipose Tissue Imaging Parameters in Patients with Cholangiocarcinoma after Surgical Resection.

Lee J, Yoo I, Hong S, Kang B, Kim J, Kim Y Int J Mol Sci. 2024; 25(7).

PMID: 38612748 PMC: 11011754. DOI: 10.3390/ijms25073939.

References
1.
Capece D, Franzoso G . Rewired lipid metabolism as an actionable vulnerability of aggressive colorectal carcinoma. Mol Cell Oncol. 2022; 9(1):2024051. PMC: 8890390. DOI: 10.1080/23723556.2021.2024051. View

2.
Di Zazzo E, Polito R, Bartollino S, Nigro E, Porcile C, Bianco A . Adiponectin as Link Factor between Adipose Tissue and Cancer. Int J Mol Sci. 2019; 20(4). PMC: 6412253. DOI: 10.3390/ijms20040839. View

3.
Takano S, Kubota T, Nishibori H, Hasegawa H, Ishii Y, Nitori N . Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res. 2009; 28(6A):3593-9. View

4.
Vaitkus J, Celi F . The role of adipose tissue in cancer-associated cachexia. Exp Biol Med (Maywood). 2016; 242(5):473-481. PMC: 5367652. DOI: 10.1177/1535370216683282. View

5.
Rubinstein M, Brown K, Iyengar N . Targeting obesity-related dysfunction in hormonally driven cancers. Br J Cancer. 2021; 125(4):495-509. PMC: 8368182. DOI: 10.1038/s41416-021-01393-y. View